research Good efficacy achieved by baricitinib in the treatment of anti-MDA5 antibody-positive dermatomyositis with alopecia areata
Baricitinib was effective in treating a patient with dermatomyositis and hair loss.
Search
for
Sort by
Research
480-510 / 1000+ results 
research Public Interest in JAK Inhibitors for Alopecia Areata: A Google Trend Analysis (Preprint)
Interest in JAK inhibitors for hair loss increased significantly after media coverage and FDA approval.
research ALOPESIA AREATA DENGAN TERAPI KOMBINASI INJEKSI PLATELET-RICH PLASMA (PRP) DAN TRIAMSINOLON ASETONID INTRALESI
The combination of PRP and triamcinolone injections improved hair growth in a man with alopecia areata.
research AYURVEDIC THERAPEUTICS IN THE MANAGEMENT OF KHALITYA: A CASEBASED EVIDENCE
Ayurvedic treatments can effectively manage hair fall.
research Tumor necrosis factor inhibitors and janus kinase inhibitors in the treatment of cicatricial alopecia: A systematic review
Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.
research Dual improvement of alopecia areata and immune thrombocytopenia with baricitinib: a case report
Baricitinib may effectively treat both alopecia areata and immune thrombocytopenia.
research Therapeutic Response of Alopecia Areata‐Associated Nail Changes to Baricitinib
Baricitinib may effectively treat nail changes in alopecia areata.
research Tofacitinib therapy for children with severe alopecia areata
Tofacitinib may help treat severe childhood alopecia areata, but risks require careful consideration.
research Elevated serum heat shock protein-70 and interleukin-15: prognostic biomarkers correlating with clinical severity and diagnostic efficacy in active alopecia areata
High levels of HSP70 and IL-15 are linked to more severe alopecia areata.
research Severe onycholysis in a card illusionist with alopecia areata universalis
Systemic steroids effectively treated severe nail issues in a card illusionist with alopecia areata.
research Patient Considerations when Using Ritlecitinib for Alopecia Areata in Adolescents: Guidance for the Clinicians
Clinicians should consider individual factors and communicate risks and benefits when prescribing ritlecitinib for adolescent alopecia areata.
research Alopecia areata clinical trial enrollment and retention outcome factors among underrepresented ethnic and racial groups: A cross-sectional study
Clinical trials for alopecia areata need better inclusion and retention of patients of color.
research The Legal Status and Liability of the OH Professional
OH professionals must clearly understand their role and responsibilities to avoid legal issues.
research The Good and Bad News About New Drugs for Treating Alopecia Areata
JAK inhibitors show promise for treating Alopecia Areata, while statins are not recommended.
research Alopecia Areata Barbae in a Nutshell
Beard alopecia areata causes patchy beard hair loss, often treatable with janus kinase inhibitors.
research EVALUATION OF THE EFFECTIVENESS OF AMRABIJA CHURNAM AND HARITAKI CHURNAM (EXTERNAL APPLICATION) IN THE MANAGEMENT OF DARUNAKA (DANDRUFF): A CASE STUDY
The Ayurvedic paste effectively relieved dandruff symptoms in a 14-year-old boy.
research OA01.03. Antisecretory and antiulcer activities of eclipta alba linn. In rats
Eclipta alba extract reduces ulcers and protects the stomach in rats.
research A CASE STUDY: MANAGEMENT OF INDRALUPTA WITH AYURVEDIC REGIMEN(ALOPECIA AREATA)
Ayurvedic Shamana therapy effectively treats alopecia areata with minimal side effects.
research Patient Profile and Treatment Characteristics of Early Ritlecitinib Initiators in the US
Ritlecitinib provides new treatment options for diverse alopecia areata patients.
research Intralesional Pentoxifylline Injection Versus Triamcinolone Acetonide in Treating localized Alopecia Areata: A Comparative Study.
Pentoxifylline is a safe and effective alternative to triamcinolone acetonide for treating localized alopecia areata.
research Dermatologist and Patient Perceptions of Treatment Success in Alopecia Areata and Evaluation of Clinical Outcome Assessments in Japan
Both dermatologists and patients in Japan agree that treatment success for alopecia areata is having 20% or less scalp hair loss.
research Population exposure–response analysis of the effect of ritlecitinib on eyebrow assessment and eyelash assessment in patients with alopecia areata
Ritlecitinib effectively regrows eyebrow and eyelash hair in alopecia areata, with 50 mg being the best dose.
research One of the best treatments for alopecia areata remains unpublished
DNCB is highly effective for treating alopecia areata with minimal long-term side effects.
research Board Certification
research A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results
Ritlecitinib and brepocitinib effectively regrow hair in alopecia areata patients.
research Alopecia Areata: Burden of Disease, Approach to Treatment, and Current Unmet Needs
Current treatments for Alopecia Areata have mixed success, and there's a need for better, more accessible options and support for affected individuals.
research Chronic Myeloid Leukemia: Part I—Real-World Treatment Patterns, Healthcare Resource Utilization, and Associated Costs in Later Lines of Therapy in the United States
Adolescents with severe alopecia incur significantly higher healthcare costs.
research Tofacitinib for the Treatment of Severe Alopecia Areata in Adults and Adolescents
Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.
research JAK inhibitors for the treatment of alopecia areata
JAK inhibitors show promise in treating moderate to severe alopecia areata.
research Real‐world experience and long‐term evaluation of tofacitinib in refractory alopecia areata: A prospective, open‐label, single‐center study in Asian Arab population
Tofacitinib is a promising treatment for severe alopecia areata, with many patients experiencing complete or partial hair regrowth.